On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B

doi:10.4254/wjh.v8.i34.1511

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 34

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6679)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

306

WORD

201

HTML

2487

Figures (1-2)

147

Tables (1-4)

173

Sum=3314

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

461

Download

1053

Sum=1514

Publishing Process of This Article

Item

Count

Browse

678

Download

1173

Sum=1851

Dec 8, 2016 (publication date) through May 2, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Dec 8, 2016; 8(34): 1511-1520
Published online Dec 8, 2016. doi: 10.4254/wjh.v8.i34.1511

Open in New Tab Full Size Figure Download Figure

Figure 1 Dynamic changes of hepatitis B surface antigen (A), hepatitis B e antigen (B), hepatitis B core antibody (C) and hepatitis B virus DNA (D) levels from baseline to 96-wk in chronic hepatitis B patients received nucleos(t)ide analogues therapy stratified by virological response at 96-wk. ^aP < 0.05; VR (+): Virological response, HBV DNA ≤ 300 copies/mL; VR (-): Without virological response; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; anti-HBc: hepatitis B core antibody; HBV: Hepatitis B virus; VR: Virological response.

Open in New Tab Full Size Figure Download Figure

Figure 2 Dynamic changes of hepatitis B surface antigen (A), hepatitis B e antigen (B), hepatitis B core antibody (C) and hepatitis B virus DNA (D) levels from baseline to 96-wk in chronic hepatitis B patients received nucleos(t)ide analogues therapy stratified by hepatitis B e antigen seroconversion at 96-wk. ^aP < 0.05; SC (+): HBeAg seroconversion; SC (-): Without HBeAg seroconversion; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; anti-HBc: hepatitis B core antibody; HBV: Hepatitis B virus; SC: HBeAg seroconversion.

Citation: Gao YH, Meng QH, Zhang ZQ, Zhao P, Shang QH, Yuan Q, Li Y, Deng J, Li T, Liu XE, Zhuang H. On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B. World J Hepatol 2016; 8(34): 1511-1520
URL: https://www.wjgnet.com/1948-5182/full/v8/i34/1511.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i34.1511